Kalbe Farma stock holds at EUR 0.04 after buyback reversal
Published on 10/30/2026 at 02:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBuyback reversal and operating backdrop
- Kalbe Farma canceled a planned IDR 500 billion share buyback amid volatile market conditions.
- First-half 2026 revenue rose 14.06 percent to IDR 19.47 trillion, according to the reviewed report.
- The company is also reviewing parts of its 2026 capital expenditure program.
Kalbe Farma stock was quoted at EUR 0.04 by Lang & Schwarz on October 29, 2026, at 22:59:19 Berlin time. The quote had a bid of EUR 0.03 and an ask of EUR 0.05. The current market backdrop follows the company's decision to cancel a planned share buyback worth up to IDR 500 billion.
Buyback canceled amid volatility
According to Bintang Bisnis, Kalbe announced the planned repurchase on September 16, with purchases initially scheduled to run from September 17 through December 17, 2026. The company later attributed the cancellation to significantly fluctuating market conditions without providing a more detailed explanation.
The report said the stock had fallen almost 40 percent from the beginning of the year before the proposed buyback was announced. That market history places the cancellation in the context of investor attention on capital allocation, although the decision itself does not establish a direct cause for any particular share-price movement.
Revenue growth meets cost pressure
Kalbe's first-half operating performance was stronger on revenue. Sales increased 14.06 percent to IDR 19.47 trillion in the first six months of 2026, while the company reviewed parts of a 2026 capital expenditure plan initially set at about IDR 1 trillion.
Separate reporting reviewed for this article said first-half net profit declined 2.8 percent to IDR 1.91 trillion, as selling expenses increased to IDR 3.85 trillion. For investors, the combination of higher sales and pressure on profitability makes the next financial results relevant for assessing the quality and durability of the growth trend.
Kalbe's businesses cover prescription medicines, consumer health products, nutrition and distribution. Retaining cash after the canceled repurchase gives management more flexibility for operations, investment or other corporate purposes, but it also removes a planned shareholder-return mechanism.
Kalbe Farma stock at a glance
- Company: PT Kalbe Farma Tbk
- ISIN: ID1000125107
- Lang & Schwarz quote: EUR 0.04 on October 29, 2026, at 22:59:19 Berlin time
- Bid / ask: EUR 0.03 / EUR 0.05
- Buyback plan: Up to IDR 500 billion, canceled
- First-half 2026 revenue: IDR 19.47 trillion, up 14.06 percent
- Business focus: Pharmaceuticals, consumer health, nutrition and distribution
Investors can follow the real-time quote of Kalbe Farma stock for subsequent price updates.
Broader developments in the Euro Stoxx 50 market environment provide a general regional reference but do not represent Kalbe Farma's home market.
More company-specific developments are available in more news and analyses on Kalbe Farma stock.
